Tag : OCTREOTIDE

Lutetium Lu 177 dotatate (177Lu-DOTATATE) is a peptide receptor radionuclide therapy (PRRT) approved for the treatment of somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The phase III NETTER-1 trial previously showed that 177Lu-DOTATATE significantly improved progression-free survival (PFS) in patients with grades 1 and 2 well-differentiated midgut NETs. However, the standard of care for GEP-NETs with a higher Kiel 67 (Ki-67) antigen presentation has yet to be established.1 The phase III NETTER-2 trial sought to evaluate 177Lu-DOTATATE as a first-line treatment in patients with advanced, grade 2/3 GEP-NETs, representing the first randomized trial to evaluate a radioligand as a first-line therapy for any metastatic solid tumor. 177Lu-DOTATATE was shown to significantly reduce the risk of progression or death, which supports its use as the standard of care for these patients.